Abstract:Purpose/Objective(s)To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia.Materials/MethodsPatients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years.ResultsFrom January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up.ConclusionsIMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline. Purpose/Objective(s)To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia. To prospectively explore the clinical and functional outcomes of chemoradiation therapy for locally advanced nasopharyngeal carcinoma (NPC), using intensity-modulated radiation therapy (IMRT) to spare the salivary glands and related swallowing structures to reduce xerostomia and dysphagia. Materials/MethodsPatients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years. Patients with locally advanced and treatment naive NPC (stage III, IVa, and IVb) were enrolled into this study. Treatment protocol was curative IMRT combined with weekly chemotherapy (cisplatin 40 mg/m2). The medial group retropharyngeal nodes were never contoured as CTV aiming to spare the pharyngeal constrictors unless they were involved. Level Ib node was selectively contoured as CTV in order to spare the submandibular glands and oral cavity. Dose prescriptions were GTV 66-70.4 Gy/30-32 Fx, CTV1 60 Gy/30-32 Fx, and CTV2 54-56 Gy/30-32 Fx. Swallowing and salivary glands function were evaluated by patient-reported, observer-rated scores before therapy and periodically after treatment through 3years. ResultsFrom January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up. From January 2008 to January 2010, 310 patients with stages III to IVb NPC were recruited into this study. With a median follow-up of 39 months, the 3-year local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastases-free survival (DMFS) were 93.6%, 95.8%, and 80%, respectively. There were no out-of-field or marginal relapse. Dysphagia and xerostomia worsened during the late course of radiation therapy and after treatment. But observer-rated and patient-reported scores recovered gradually over time 3 months after therapy. At 9 months after radiation therapy, both patient-reported and observer-rated dysphagia were absent or minimal, and this situation continued until the last follow-up. Patient-reported scores showed that xerostomia began to improve from 3 to 15 months after radiation therapy, and then became steady until the last follow-up. ConclusionsIMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline. IMRT concurrent with weekly chemotherapy aiming to reduce xerostomia and dysphagia can be safely performed for locally advanced NPC and has high locoregional control rates. Distant metastasis remains the main failure pattern. Long-term patient-reported and observer-rated swallowing and salivary glands function were only slightly worse than baseline.

Dosimetry of Submandibular Glands on Xerostomia for Nasopharyngeal Carcinoma

[The Relationship Between the Parotid Glands Function and the Dose-Volume Effect in Nasopharyngeal Carcinoma Patients with Intensity-Modulated Radiation Therapy].

Oncological Outcome of Patients with Salivary Gland Cancer Treated with Surgery and Postoperative Intensity-Modulated Radiotherapy: a Retrospective Study

Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients

A Risk Prediction Model by LASSO for Radiation-Induced Xerostomia in Patients With Nasopharyngeal Carcinoma Treated With Comprehensive Salivary Gland–Sparing Helical Tomotherapy Technique

Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma: Virtual Touch Tissue Quantification of Submandibular Gland

Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models

Radiation-Induced Xerostomia in Patients with Head and Neck Cancer Treated with Comprehensive Salivary Gland-Sparing Helical Tomotherapy Technique: Based on a Backpropagation Artificial Neural Network

Impact on xerostomia for patients with nasopharyngeal carcinoma treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.

Magnetic Resonance Sialography for Investigating Major Salivary Gland Duct System after Intensity-Modulated Radiotherapy of Nasopharyngeal Carcinoma

Superficial Parotid Lobe-Sparing Delineation Approach: A Better Method Of Dose Optimization To Protect The Parotid Gland In Intensity-Modulated Radiotherapy For Nasopharyngeal Carcinoma

Salivary gland function in nasopharyngeal carcinoma before and late after intensity-modulated radiotherapy evaluated by dynamic diffusion-weighted MR imaging with gustatory stimulation

Application of Diffusion Kurtosis Imaging in Evaluating Acute Xerostomia in Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy

Potential predictive value of IVIM MR for xerostomia in nasopharyngeal carcinoma

Predictive Model and Precaution for Oral Mucositis During Chemo-Radiotherapy in Nasopharyngeal Carcinoma Patients

Magnetic Resonance Sialography to Evaluate Radiation-Induced Xerostomia in Patients with Early-Stage Nasopharyngeal Carcinoma

Apparent Diffusion Coefficient Histogram Analysis Can Evaluate Radiation-Induced Parotid Damage And Predict Late Xerostomia Degree In Nasopharyngeal Carcinoma

Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study

Selective Nodal Irradiation by Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma Aiming to Reduce Dysphagia and Xerostomia

Relationship between the parotid glands function and the dose-volume effect in nasopharyngeal carcinoma patients with intensity-modulated radiotherapy by radionuclide imaging

Multimodal Data Integration to Predict Severe Acute Oral Mucositis of Nasopharyngeal Carcinoma Patients Following Radiation Therapy